Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Other Gross PP&E Adjustments (2016 - 2025)

Ani Pharmaceuticals' Other Gross PP&E Adjustments history spans 15 years, with the latest figure at $114.5 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 13.85% year-over-year to $114.5 million; the TTM value through Dec 2025 reached $114.5 million, up 13.85%, while the annual FY2025 figure was $114.5 million, 13.85% up from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was $114.5 million at Ani Pharmaceuticals, up from -$20.3 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $114.5 million in Q4 2025 and bottomed at -$60.3 million in Q1 2025.
  • The 5-year median for Other Gross PP&E Adjustments is $36.2 million (2021), against an average of $25.1 million.
  • The largest annual shift saw Other Gross PP&E Adjustments skyrocketed 34.39% in 2022 before it tumbled 217.99% in 2024.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $75.6 million in 2021, then rose by 0.44% to $76.0 million in 2022, then rose by 2.07% to $77.5 million in 2023, then rose by 29.74% to $100.6 million in 2024, then increased by 13.85% to $114.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Other Gross PP&E Adjustments are $114.5 million (Q4 2025), -$20.3 million (Q3 2025), and -$40.7 million (Q2 2025).